Pictet Asset Management Holding SA Has $20.07 Million Holdings in Enliven Therapeutics, Inc. $ELVN

Pictet Asset Management Holding SA decreased its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 6.8% in the 4th quarter, Holdings Channel reports. The fund owned 1,303,235 shares of the company’s stock after selling 94,852 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Enliven Therapeutics were worth $20,070,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ELVN. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after buying an additional 930 shares during the period. Quantbot Technologies LP grew its holdings in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Enliven Therapeutics in the 4th quarter valued at approximately $95,000. Finally, AlphaQuest LLC bought a new stake in Enliven Therapeutics in the 3rd quarter valued at approximately $96,000. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Stock Up 1.1%

NASDAQ:ELVN opened at $41.70 on Friday. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of -22.42 and a beta of 0.32. Enliven Therapeutics, Inc. has a twelve month low of $14.78 and a twelve month high of $48.53. The stock’s 50 day moving average price is $36.23 and its two-hundred day moving average price is $26.83.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.06). As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $29.04, for a total value of $145,200.00. Following the completion of the sale, the insider directly owned 740,188 shares in the company, valued at approximately $21,495,059.52. This trade represents a 0.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Richard A. Heyman sold 1,230 shares of Enliven Therapeutics stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total value of $32,201.40. Following the transaction, the director owned 22,647 shares of the company’s stock, valued at $592,898.46. The trade was a 5.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 16,230 shares of company stock worth $473,201 over the last quarter. 25.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Mizuho raised their target price on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, March 25th. Finally, HC Wainwright boosted their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $43.40.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.